Quoin Pharmaceuticals, LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Quoin Pharmaceuticals Insider's Stake Dips Below 5% Threshold Following Investor Warrant Exercises
Dr. Michael Myers' beneficial ownership in Quoin Pharmaceuticals Ltd. has decreased to 4.9% due to dilution from other investors exercising warrants in the company's December 2024 offering.
NASDAQ
SCHEDULE 13D/A: Denise Carter's Stake in Quoin Pharmaceuticals Drops Below 5% Following Other Investors' Warrant Exercises
Denise Carter's beneficial ownership in Quoin Pharmaceuticals Ltd. decreased to 4.9% as of January 27, 2025, primarily due to the exercise of warrants by other investors in the company's December 2024 offering, which increased the total outstanding shares.
NASDAQ
SCHEDULE 13D: Quoin Pharmaceuticals COO Denise Carter Boosts Stake to 6.9% Following Public Offering and Option Grants
Quoin Pharmaceuticals Ltd.'s Chief Operating Officer, Denise Carter, has increased her beneficial ownership in the company to 6.9% through recent share purchases in a public offering and new option grants, as detailed in a Schedule 13D filing.
NASDAQ
SCHEDULE 13D: Quoin Pharmaceuticals CEO Dr. Michael Myers Boosts Stake to 6.9% Through Recent Share and Warrant Purchases
Quoin Pharmaceuticals Ltd.'s CEO and Chairman, Dr. Michael Myers, has increased his beneficial ownership in the company to 6.9% through recent purchases in a public offering and the grant of new stock options, signaling continued investment in the company's future.